idiopathic pulmonary fibrosis

Biotech

Pliant surges as phase 2 data raise hopes for lung disease asset

With phase 2 data supporting more development, the biotech boasted a 60%-plus stock surge on Monday morning.
Nick Paul Taylor Jul 11, 2022 9:25am

‍AstraZeneca collects 2nd lung fibrosis target from BenevolentAI

May 24, 2022 9:05am

AbbVie ditches Morphic's fibrosis program after 'safety signal'

Feb 24, 2022 3:25pm

Endeavor nabs $101M for IPF, cancer trials—and asset shopping

Feb 7, 2022 8:00am

Insilico begins first human trial of AI-designed fibrosis drug

Nov 30, 2021 4:00pm

Blade runs to Wall St. at $353M SPAC deal for 2 trials in 2022

Nov 8, 2021 9:40am